You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Amoxil (amoxicillin) SPC and PIL updates

Please note that the Amoxil SPCs and PILs were updated on 21st April 2016 in line with European Harmonisation Process. Please see the Amoxil product page for further information. 

View our products

View our products

Find comprehensive information on our products including resources for patients.

Expert perspectives

Respiratory Knowledge Base

Watch videos on everything from disease and patient management to research and development. 

Find out more

Adverse events should be reported. Reporting forms and information can be found at : www.hpra.ie.
Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Amoxil, Relvar, Triumeq and Ellipta are registered trademarks of the GSK group of companies.